LUCD logo
LUCD
Lucid Diagnostics

Expanded Reimbursement And Cash-Pay Programs Will Open Future Markets

AN
AnalystConsensusTarget
AnalystConsensusTarget
Not Invested
Consensus Narrative from 6 Analysts
Published
12 Apr 25
Updated
08 Aug 25
AnalystConsensusTarget's Fair Value
US$3.79
73.7% undervalued intrinsic discount
08 Aug
US$1.00
Loading
1Y
26.2%
7D
-0.3%

Author's Valuation

US$3.8

73.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Narrative
Updates3

Shared on01 May 25
Fair value Increased 4.17%

Read more

Shared on24 Apr 25
Fair value Decreased 4.00%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

Shared on17 Apr 25

Read more